Shannon L. Winski

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 507 citations

Medicine, Medicinal Chemistry, Oncology +9

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 433 citations · Full text

Medicine, Oncology, Pharmacology +16

Selective RET kinase inhibition for patients with RET-altered cancers

Vivek Subbiah, Vamsidhar Velcheti, Brian B. Tuch et al. · Annals of Oncology · 2018 · 429 citations · Full text

Medicine, Oncology, Pharmacology +16

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H

David Siegel, Susan M. McGuinness, Shannon L. Winski et al. · Pharmacogenetics · 1999 · 238 citations

Medicine, Genetics, Molecular Genetics +13

Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1

David J. Siegel, Adil Anwar, Shannon L. Winski et al. · Molecular Pharmacology · 2001 · 208 citations

Life Sciences, Biochemistry, Molecular Biology +17